Genmab — December 2018
-
Det må vel betegnes som overordentlig positivt:-)
-
in Syros press release
SY-1425 Induced CD38 Expression in Majority of Patients in Daratumumab Combination Cohort in Relapsed/Refractory AML and Higher-Risk MDS Patientshttps://www.businesswire.com/news/home/20181202005039/en/Syros-Announces-Promising-Clinical-Data-Ongoing-Phase 2 -
-
over 52,000 patients treated https://twitter.com/NorthTxMSG/status/1069281456092925952
-
-
-
Vores ven Vincent Ra...https://twitter.com/vincentrk/status/1069262798931148800?s=21
-
Skal vi være bange for en kombo uden Dara? Fx KCRD? Nogen, der kender til den
-
Andre muligheder er også triplerne KRd og VRd. Dara bliver testet som kvadruplet i begge kombinationer. Og så bliver spørgsmålet om dara gør det så meget bedre, at det er pengene værd. Nu så vi med Maia at dara fordobler effektiviteten ift Rd. Om det er pengene værd vil vise sig. Rajkumars hovedtanke - cost-effectiveness - er relevant i de fleste sammenhænge.
-
Det var dog en
voldsom forskel til Griffen og Lyra hvor der forventes 80% i MRD-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind